South African Mutations of the CCR5 Coreceptor for HIV Modify Interaction With Chemokines and HIV Envelope Protein

被引:10
|
作者
Folefoc, Asongna T. [2 ,3 ]
Fromme, Bernhard J. [2 ,3 ,4 ]
Katz, Arieh A. [2 ,3 ]
Flanagan, Colleen A. [1 ]
机构
[1] Univ Witwatersrand, Sch Med, Sch Physiol, ZA-2193 Johannesburg, South Africa
[2] Univ Cape Town, Fac Hlth Sci, MRC, Res Grp Receptor Biol,Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa
[3] Univ Cape Town, Fac Hlth Sci, Div Med Biochem, ZA-7925 Cape Town, South Africa
[4] Biosci Div, Sci Grp, Cape Town, South Africa
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
CCR5 coreceptor mutants; CCR5; expression; Env-directed fusion; IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-TERMINAL DOMAIN; RECEPTOR CCR5; GP120; BINDING; MIP-1; ALPHA; MOLECULAR-INTERACTIONS; FUNCTIONAL EXPRESSION; COUPLED RECEPTORS; RESISTANCE ALLELE; LIGAND-BINDING;
D O I
10.1097/QAI.0b013e3181e0c7b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CCR5 chemokine receptor is the major coreceptor for HIV-1 and the receptor for CC-chemokines, MIP-1 alpha, MIP-1 beta, and regulated upon activation normal T-cell-expressed and secreted. Individuals, who are homozygous for the nonfunctional CCR5 Delta 32 allele, are largely resistant to HIV-1 infection. Four unique mutations that affect the amino acid sequence of CCR5 have been identified in South Africa. We have assessed the effect of these mutations on CCR5 interactions with chemokines and HIV Envelope protein. The Leu(107)Phe mutation did not affect CCR5 expression, chemokine binding, intracellular signaling, or interaction with Envelope. The Arg(225)Gln mutant was similar to wild-type CCR5, but ligand-independent intracellular signaling suggests that it is partially constitutively active. The Asp(2)Val mutation decreased chemokine-binding affinity, chemokine-stimulated intracellular signaling, and receptor expression. It also decreased HIV Envelope-mediated cell fusion. The Arg(225)Stop mutant showed no measurable chemokine binding or signaling and no measurable expression of CCR5 at the cell surface or within the cell. Consistent with lack of cell surface expression, it did not support envelope-mediated cell fusion. These results show that South African CCR5 variants have a range of phenotypes in vitro that may reflect altered chemokine responses and susceptibility to HIV infection in individuals who carry these alleles.
引用
收藏
页码:352 / 359
页数:8
相关论文
共 50 条
  • [31] Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection
    Herrera-Carrillo, Elena
    Ben Berkhout
    PLOS ONE, 2017, 12 (05):
  • [32] A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors
    Moore, John P.
    Kuritzkes, Daniel R.
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 118 - 124
  • [33] Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
    Tebas, Pablo
    Stein, David
    Tang, Winson W.
    Frank, Ian
    Wang, Shelley Q.
    Lee, Gary
    Spratt, S. Kaye
    Surosky, Richard T.
    Giedlin, Martin A.
    Nichol, Geoff
    Holmes, Michael C.
    Gregory, Philip D.
    Ando, Dale G.
    Kalos, Michael
    Collman, Ronald G.
    Binder-Scholl, Gwendolyn
    Plesa, Gabriela
    Hwang, Wei-Ting
    Levine, Bruce L.
    June, Carl H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (10) : 901 - 910
  • [34] Elucidating a Key Anti-HIV-1 and Cancer-Associated Axis: The Structure of CCL5 (Rantes) in Complex with CCR5
    Tamamis, Phanourios
    Floudas, Christodoulos A.
    SCIENTIFIC REPORTS, 2014, 4
  • [35] Sex Affects Cognitive Outcomes in HIV-1 Tat Transgenic Mice: Role of CCR5
    Simons, Chloe A.
    Kim, Sarah
    Hahn, Yun K.
    Boake-Agyei, Ama
    Nass, Sara R.
    Vo, Phu
    Hauser, Kurt F.
    Knapp, Pamela E.
    ASN NEURO, 2025, 17 (01):
  • [36] Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes
    Roche, Michael
    Borm, Katharina
    Flynn, Jacqueline K.
    Lewin, Sharon R.
    Churchill, Melissa J.
    Gorry, Paul R.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (10) : 1091 - 1106
  • [37] Association Between HIV-1 Tropism and CCR5 Human Haplotype E in a Caucasian Population
    Huik, Kristi
    Avi, Radko
    Uibopuu, Helen
    Pauskar, Merit
    Margus, Tonu
    Karki, Tonis
    Krispin, Tonu
    Kool, Piret
    Rueuetel, Kristi
    Talu, Ave
    Abel-Ollo, Katri
    Uuskuela, Anneli
    Carrillo, Andrew
    He, Weijing
    Ahuja, Sunil K.
    Lutsar, Irja
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (03) : 239 - 244
  • [38] CCR5 Antagonists in the Treatment of HIV-Infected Persons: Is Their Cancer Risk Increased, Decreased, or Unchanged?
    McNiff, Todd
    Dezube, Bruce J.
    AIDS READER, 2009, 19 (06) : 218 - +
  • [39] Efficient Modification of the CCR5 Locus in Primary Human T Cells With megaTAL Nuclease Establishes HIV-1 Resistance
    Ibarra, Guillermo S. Romano
    Paul, Biswajit
    Sather, Blythe D.
    Younan, Patrick M.
    Sommer, Karen
    Kowalski, John P.
    Hale, Malika
    Stoddard, Barry
    Jarjour, Jordan
    Astrakhan, Alexander
    Kiem, Hans-Peter
    Rawlings, David J.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2016, 5 : 1 - 10
  • [40] Preintegration HIV-1 Inhibition by a Combination Lentiviral Vector Containing a Chimeric TRIM5α Protein, a CCR5 shRNA, and a TAR Decoy
    Anderson, Joseph S.
    Javien, John
    Nolta, Jan A.
    Bauer, Gerhard
    MOLECULAR THERAPY, 2009, 17 (12) : 2103 - 2114